Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599573 | 1.00 | RAF1 (0.39) | RAF1KCNH2TRPV1RORCIDO1 | |
| SCHEMBL3589818 | 0.87 | TRPV1 (0.38) | RAF1TRPV1RORCIDO1TDO2 | |
| SCHEMBL3606831 | 0.86 | TRPV1 (0.36) | TRPV1RORCIDO1TDO2 | |
| SCHEMBL3606830 | 0.86 | TRPV1 (0.36) | TRPV1RORCIDO1TDO2 | |
| SCHEMBL3591545 | 0.85 | TRPV1 (0.39) | RAF1KCNH2TRPV1IDO1TDO2 | |
| SCHEMBL3591544 | 0.85 | TRPV1 (0.39) | RAF1KCNH2TRPV1IDO1TDO2 | |
| SCHEMBL3603405 | 0.81 | TRPV1 (0.42) | TRPV1IDO1TDO2 | |
| SCHEMBL3603402 | 0.81 | TRPV1 (0.42) | TRPV1IDO1TDO2 | |
| SCHEMBL3595558 | 0.80 | TRPV1 (0.51) | RAF1KCNH2TRPV1 | |
| SCHEMBL4451688 | 0.79 | RAF1 (0.42) | RAF1KCNH2TRPV1CYP1A2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | RAF1 1753/4885KCNH2 416/4885TRPV1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.